SOLNA, Sweden & ANTONY, France--(BUSINESS WIRE)--Aerocrine AB (STO:AERO.B) and Stallergenes S.A (Euronext Paris CAC small) today announce the signing of an exclusive multi-year distribution agreement ...
NEW PROVIDENCE, N.J., March 4 /PRNewswire/ -- Aerocrine, Inc. (www.aerocrine.com) today announced that NIOX MINO (www.nioxmino.com), a hand- held point-of-care device for the measurement of airway ...
SOLNA, Sweden, 12 February 2009 - Aerocrine AB (OMX Nordic Exchange: AERO) has reported the recent publication of a UK study evaluating the effect of routine inflammation measurement in asthma. The ...
Aerocrine AB (OMX Nordic Exchange: AERO) announces that Health Canada’s Therapeutic Products Directorate has authorized Aerocrine’s latest NIOX MINO® for use in identifying allergic airway ...
March 11, 2008 — The US Food and Drug Administration (FDA) has granted 510(k) clearance for a handheld device for the measurement of airway inflammation, an intraosseous infusion system for use in ...
Aerocrine AB, a medical technology company focused on the improved management and care of patients with inflammatory airway diseases, has signed an distribution agreement with Shanghai Pharmaceuticals ...
Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
SOLNA, Sweden--(BUSINESS WIRE)-- Regulatory News: Aerocrine (STO:AERO-B) secures long-term financing. US clinical sales grew by 45%. January - March 2013 Global Net sales decreased by 14% to SEK 33.7m ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
Roberto Gradnik, Chief Executive OfficerTel. +33 1 55 59 20 04orChristian Thiry, Chief Financial OfficerTel. +33 1 55 59 20 95e-mail: orPavie Finance: Lucile de FraguierTel. +44 208 248 2793e-mail: ...
Aerocrine AB (OMX Nordic Exchange: AERO) announces that Health Canada’s Therapeutic Products Directorate has authorized Aerocrine’s latest NIOX MINO® for use in identifying allergic airway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback